Key Financial Performance (Consolidated)

Quarterly Performance (Q1 FY27 vs Q1 FY26)

  • Revenue from Operations: ₹697.2 crore, up 28.2% from ₹543.7 crore
  • Total Expenditure: ₹616.6 crore, up 28.9% from ₹475.8 crore
  • Cost of Goods Sold: ₹490.8 crore, up 32.2% from ₹371.3 crore
  • Employee Benefits Expense: ₹44.1 crore, up 17.6% from ₹37.5 crore
  • Other Expenses: ₹81.7 crore, up 21.9% from ₹67.0 crore
  • EBITDA: ₹80.6 crore, up 18.7% from ₹67.9 crore
  • EBITDA Margin: 11.6%, down 90 bps from 12.5%
  • Other Income: ₹3.2 crore, up 166.7% from ₹1.2 crore
  • Finance Costs: ₹11.0 crore, up 93.0% from ₹5.7 crore
  • Depreciation and Amortization: ₹25.6 crore, up 43.8% from ₹17.8 crore
  • Share of Profit of Joint Venture and Associate: ₹0.5 crore (flat YoY)
  • Profit Before Tax: ₹47.7 crore, up 3.5% from ₹46.1 crore
  • Tax Expense: ₹12.6 crore, up 0.8% from ₹12.5 crore
  • Profit After Tax: ₹35.1 crore, up 4.5% from ₹33.6 crore
  • PAT Margin: 5.0%, down 120 bps from 6.2%
  • Diluted EPS: ₹6.3, up from ₹6.1

Annual Performance (FY26 vs FY25)

  • Revenue from Operations: ₹2,396.4 crore, up 15.2% from ₹2,080.3 crore
  • EBITDA: ₹286.0 crore, up 7.9% from ₹265.1 crore
  • EBITDA Margin: 11.9%, down 80 bps from 12.7%
  • PAT: ₹149.2 crore, up 9.4% from ₹136.4 crore
  • PAT Margin: 6.2%, down 40 bps from 6.6%
  • Diluted EPS: ₹26.9, up from ₹24.6

Segment-wise Performance

Quarterly Revenue Break-up (Q1 FY27)

  • Home, Personal Care and Performance Chemicals (HPPC): 28% YoY growth
  • Textile Specialty Chemicals (TSC): 28% YoY growth
  • Animal Health and Nutrition (AHN): 27% YoY growth
  • Total Revenue Growth: 28% YoY, 2% QoQ

Segment Quarterly Trends

  • HPPC: 4% QoQ growth
  • TSC: -6% QoQ decline
  • AHN: -10% QoQ decline

Key Operational Developments

International Expansion

  • Established greenfield blending facility in Thailand through subsidiary Unistar Thai
  • Installed capacity: 5,000 MTPA with capabilities across powders, granules, and liquids
  • Designed to offer customized formulations for Southeast Asian markets
  • Aims to enhance supply-chain efficiency and local market responsiveness

Non-Core Asset Monetization

  • Completed sale of Andheri office during Q1 FY27
  • Follows sale of Kanjurmarg office in previous quarter (Q4 FY26)
  • Part of ongoing strategy to monetize non-core assets

Manufacturing Capacity Overview

  • Total Installed Capacity: 387,100 MTPA (including Unitop Chemicals & Tristar Intermediates)
  • Manufacturing Facilities: 4 locations (Silvassa, Dahej, Sarigam)
  • R&D Facilities: Multiple locations including state-of-the-art facility at IIT Mumbai campus

Management Commentary

Mr. Edward Menezes (Promoter & Executive Chairman) and Mr. Sunil Chari (Promoter & Managing Director) stated:

  • Commenced FY27 with strong 28% YoY revenue growth driven by domestic momentum and international expansion
  • All core segments (HPPC, TSC, AHN) delivered 27-28% YoY growth
  • International business showed steady progress with higher wallet share with global partners
  • Focused investments in new capabilities showing improving capacity utilization
  • Priority on driving optimal utilization, strengthening product portfolio, and enhancing operational efficiencies
  • Healthy balance sheet and integrated manufacturing platform position company for emerging opportunities

Historical Financial Performance Trends

  • 25% Revenue CAGR (FY19-26)
  • 18% PAT CAGR (FY19-26)
  • Consistent growth trajectory over past four years through organic and inorganic strategies

Corporate Structure

  • Incorporated as Rossari Labtech partnership firm in March 2003
  • Converted to joint stock company as Rossari Biotech Limited in August 2009
  • Listed on BSE and NSE in 2020

Investor Conference Call Details

  • Date: Monday, July 20, 2026
  • Time: 5:00 PM IST
  • Dial-in: +91 22 6280 1141 / 7115 8042
  • Pre-registration: Available via Chorus Call Diamond Pass